Skip to main content
Sign In

Home Future StudentsCurrent StudentsFaculty & StaffPatientsAlumni
 

Publications

                                     

​Extended Survival of Glioblastoma Patients with Dynamic Clonal Fluctuations After

Chemoprotective Hematopoietic Stem Cell Gene Therapy

Adair JE,  Beard BC, Trobridge GD, Neff T, Rockhill J​​​K, Silbergeld DL, Mrugala M,  Kiem HP 

Sci Transl Med 9 May 2012 4:133ra57


Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

Heidel FH, Bullinger L,  Feng Z,  Wang Z,  Neff TA, Stein L,  Kalaitzidis D, Lane SW,  Armstrong SA

Cell Stem Cell. 2012 Apr 6; 10(4):412-24


The Polycomb Repressive Complex 2 Is Required For MLL-AF9 Leukemia 

Neff T, Sinha AU, Kluk MJ, Zhu N,  Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33.


An Unusual Case of Congenital Primitive Neuroectodermal Tumor With Ocular Metastasis.

Salgado C, Neff T*, Frazier L, Vargas SO, Vanderveen D. (Case report)

J Pediatr Hematol Oncol. 2012 Mar;34(2):e69-71.*corresponding author


Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients.

Beard BC, Sud R, Keyser KA, Ironside C, Neff T, Gerull S, Trobridge GD, Kiem HP.

Blood. 2009 May 21;113(21):5094-103. 


Hematopoietic stem cell engraftment: a direct comparison between intramarrow and intravenous injection in nonhuman primates.

Jung CW, Beard BC, Morris JC, Neff T, Beebe K, Storer BE, Kiem HP.

Exp Hematol. 2007 Jul;35(7):1132-9.


In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs.

Gerull S, Beard BC, Peterson LJ, Neff T, Kiem HP.

Hum Gene Ther. 2007 May;18(5):451-6.


Improved short-term engraftment of lentivirally versus gammaretrovirally transduced allogeneic canine repopulating cells.

Neff T, Gerull S, Peterson LJ, Kiem HP.

J Gene Med. 2007 May;9(5):357-61.


Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy.

Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem HP.  

Blood. 2005 Feb 1;105(3):997-1002. 


Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol.

Horn PA, Keyser KA, Peterson LJ, Neff T, Thomasson BM, Thompson J, Kiem HP. 

Blood. 2004 May 15;103(10):3710-6.

​

Efficient gene transfer to hematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells.

 Neff T, Peterson LJ, Morris JC, Thompson J, Zhang X, Horn PA, Thomasson BM, Kiem HP.  

Mol Ther. 2004 Feb;9(2):157-9.  


Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model.

Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA, Schmidt M, Georges GE, von Kalle C, Kiem HP. 

J Clin Invest. 2003 Nov;112(10):1581-8.


Pharmacologically regulated in vivo selection in a large animal. 

Neff T, Horn PA, Valli VE, Gown AM, Wardwell S, Wood BL, von Kalle C, Schmidt M, Peterson LJ, Morris JC, Richard RE, Clackson T, Kiem HP, Blau CA.

Blood. 2002 Sep 15;100: 2026-2031


Receptor specificity in the self renewal and differentiation of primary  multipotential hemopoietic cells. 

Zeng H, Jin L, Richard RE, Neff T, Otto KG, Thomis D, Miller AD, Blau CA 

Blood. 2001 Jul 15;98(2):328-34.


Marrow sensitization to 5-fluorouracil using the ligands for Flt-3 and c-Kit.

Jin L, Neff T, Blau CA. 

Exp Hematol. 1999 Mar 27(3):520-5.


Cytokine prestimulation as a gene therapy strategy: implications for using the

MDR1 gene as a dominant selectable marker.

Blau CA, Neff T, Papayannopoulou T. 

Blood. 1997 Jan 1;89(1):146-54.


The hematological effects of folate analogs: implications for using the

dihydrofolate reductase gene for in vivo selection.

Blau CA, Neff T, Papayannopoulou T. 

Hum Gene Ther. 1996 Nov 10;7(17):2069-78.


Forced expression of cytidine deaminase confers resistance to cytosine

arabinoside and gemcitabine. 

Neff T, Blau CA. 

Exp Hematol. 1996 Sep;24(11):1340-6.


Reviews:

Chromatin maps, histone modifications and leukemia.​

Neff T, Armstrong SA.

Leukemia. 2009 Jul;23(7):1243-51. Review.


Survival of the fittest: In vivo selection and stem cell gene therapy. Review.

Neff T, Beard BC, Kiem HP. 

Blood. 2006 Mar 1;107(5):1751-60.


Stem cell gene transfer-efficacy and safety in large animal studies. Review.

Horn PA, Morris JC, Neff T, Kiem HP. 

Mol Ther. 2004 Sep;10(3):417-31.

​

Pharmacologically regulated cell therapy. Review.

 Neff, T and Blau, CA 

Blood. 2001 May 1;97(9):2535-40. 


Stem cell gene therapy, position effects and chromatin insulators. Review.

Neff T, Shotkoski F, Stamatoyannopoulos G​

Stem Cells. 1997;15 Suppl 1:265-71. 


MD-Thesis

1995-1996 “Cytidine-Deaminase as a Selectable Marker for Gene Therapy”

University of Washington, Seattle, WA and Prof. Bernhard Kornhuber, Goethe University, Frankfurt a.M.

- summa cum laude – (11/1999)